Levocetirizine/montelukast
Alternative Names: HCP 1102; Montelukast/levocetirizineLatest Information Update: 22 Jul 2022
At a glance
- Originator Hanmi Pharmaceutical
- Class Acetates; Anti-inflammatories; Antiallergics; Antiasthmatics; Antidementias; Antivirals; Bronchodilators; Neuroprotectants; Nonsedating antihistamines; Nootropics; Piperazines; Quinolines; Small molecules
- Mechanism of Action Histamine H1 receptor antagonists; Leukotriene D4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Perennial allergic rhinitis
- No development reported Allergic rhinitis
Most Recent Events
- 22 Jul 2022 No development reported - Phase-III for Perennial allergic rhinitis in South Korea (PO)
- 24 Jun 2019 Hanmi Pharmaceutical completes phase III clinical trials in Perennial allergic rhinitis in South Korea (PO) (NCT04324918)
- 28 Jan 2019 Chemical structure information added